Veracyte, Inc. (NASDAQ:VCYT) CEO Bonnie H. Anderson Sells 20,354 Shares
Veracyte, Inc. (NASDAQ:VCYT) CEO Bonnie H. Anderson sold 20,354 shares of Veracyte stock in a transaction that occurred on Tuesday, January 12th. The stock was sold at an average price of $50.20, for a total value of $1,021,770.80. Following the completion of the sale, the chief executive officer now directly owns 268,938 shares in the company, valued at $13,500,687.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Veracyte stock opened at $49.95 on Thursday. Veracyte, Inc. has a one year low of $13.90 and a one year high of $63.55. The company has a market cap of $2.89 billion, a price-to-earnings ratio of -79.29 and a beta of 0.62. The business’s 50 day moving average price is $52.97 and its 200 day moving average price is $39.42.
Veracyte (NASDAQ:VCYT) last announced its quarterly earnings data on Monday, November 2nd. The biotechnology company reported ($0.08) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.13. Veracyte had a negative return on equity of 13.35% and a negative net margin of 27.49%. The firm had revenue of $31.12 million for the quarter, compared to the consensus estimate of $24.85 million. Equities analysts predict that Veracyte, Inc. will post -0.77 EPS for the current fiscal year.
VCYT has been the topic of a number of research analyst reports. SVB Leerink lifted their price target on Veracyte from $37.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 3rd. ValuEngine lowered Veracyte from a “buy” rating to a “hold” rating in a research note on Tuesday, December 1st. Lake Street Capital lifted their price target on Veracyte from $40.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, December 17th. BTIG Research lifted their price target on Veracyte from $42.00 to $56.00 and gave the stock a “buy” rating in a research note on Thursday, December 17th. Finally, BidaskClub lowered Veracyte from a “buy” rating to a “hold” rating in a research note on Wednesday, December 30th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $47.57.
Veracyte Company Profile
Veracyte, Inc operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test for assessing risk of distant recurrence.
See Also: CAC 40 Index
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.